Omar Nadeem, MD, discusses conclusions and next steps based on the CAR-PRISM trial in smoldering myeloma.
Omar Nadeem, MD
Advertisement
Omar Nadeem, MD, is clinical director of the Myeloma Immune Effector Cell Therapy Program at the Dana-Farber Cancer Institute.
Articles by Omar Nadeem, MD
In an in-depth interview, Omar Nadeem, MD, explores the promising findings from 20 patients with smoldering myeloma treated with cilta-cel.
Omar Nadeem, MD, discusses results of the CAR-PRISM trial in smoldering myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Phase 3 Trial Initiated for Rinzimetostat Plus Darolutamide in mCRPC
2
Pembro Monotherapy Boosts PFS Vs Chemo in dMMR Endometrial Cancer
3
Sac-TMT Plus Pembrolizumab Beats Chemo-Immunotherapy in PD-L1–Negative NSCLC
4
FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer
5